CEU Statement: UK MEC 2016 Update
Date: 29 Mar 2017
Type: FSRH Clinical Guidance and Clinical Statements
Change of UKMEC category for use of progestogen-only injectable contraception by women at high risk of HIV infection from UKMEC1 to UKMEC2
The UKMEC category for use of progestogen-only injectable contraception by women at high risk of acquiring HIV is changing from UKMEC1 (no restriction to use) to UKMEC2 (benefits of use generally outweigh risks).
Why is this change being made?
Some studies, carried out in areas of high HIV prevalence, have found an association between use of progestogen-only injectables (but not other hormonal contraception) and increased risk of acquisition of HIV. The studies DO NOT establish whether use of progestogen-only injectables causes the increased risk or whether this is due to confounding factors (eg non use of condoms). The change is being made because it is considered important that women at high risk of HIV are made aware of the available evidence so that they can make fully informed contraceptive choices.
What does this change mean in practice?
Women at high risk of HIV should continue to be offered progestogen-only injectable contraception alongside all other suitable contraceptive methods. They should be made aware of the study findings and the limitations of these. Reliable condom use should be encouraged.
Read the full statement from the UKMEC 2016 Guideline Development Group below.